PI Industries (PIIND) Q4 24/25 earnings summary

Executive summary

• Achieved 6% standalone revenue growth and 17% EBIT growth for FY25, with consolidated revenue up 4% year-over-year and a three-year CAGR of 15%.

• Commercialized 13 new products (6 exports, 7 domestic) in FY25, with strong biologicals growth and new product launches.

• Maintained industry-leading financial metrics and continued transformation into a diversified life sciences powerhouse.

• Board approved audited results for FY25 with unmodified audit opinions and announced key management and board appointments.

• Strategic focus on innovation, sustainability, and expanding global partnerships in ag chem, pharma, and biologicals.

Financial highlights

• FY25 consolidated revenue reached Rs 79,778 million, up 4% year-over-year; standalone revenue was Rs 75,712 million.

• FY25 consolidated EBITDA at Rs 21,833 million, up 8%; full-year EBITDA margin: 27.4%.

• Net profit for FY25 was Rs 16,602 million, down 1% year-over-year; standalone net profit was Rs 18,665 million.

• Net worth increased to Rs 111,170 million; cash and cash equivalents at year-end stood at Rs 5,923 million.

• Final dividend for FY25 declared at Rs 10 per share, total Rs 16 per share including interim dividend.

Outlook and guidance

• Maintains single-digit, mid-level growth guidance for FY26, with stronger performance expected in H2 as global headwinds ease.

• EBITDA margin guidance for FY26 is around 25%; CapEx guidance for FY26: Rs 8,000–9,000 million.

• Pharma business expected to see positive trends and potential breakeven over FY26–FY28, with >75% revenue growth in Pharma CRDMO targeted for FY26.

• Aggressive commercialization of 8-10 new products planned for FY26; continued focus on biologicals and portfolio diversification.

• Board recommended a final dividend and confirmed the 78th AGM will be held on August 14, 2025.